By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

CVS’s expansion into primary care is expected to drive long-term growth, while Gilead’s strong pipeline and market position in virology and oncology support its continued dividend growth.

CVS Health Corp., one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from ...

CVS Health Corp(NYSE: CVS), Gilead Sciences, Inc.(NASDAQ: GILD), and Omega Healthcare Investors Inc(NYSE: OHI) are three awesome-sauce healthcare stocks that operate in different corners of the ...

CVS Health Corp(NYSE: CVS), Gilead Sciences, Inc.(NASDAQ: GILD), and Omega Healthcare Investors Inc(NYSE: OHI) are three awesome-sauce healthcare stocks that operate in different corners of the ...